Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

24.34 -0.70 (-2.80%)
Official Closing Price Updated: 4:15 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 672,474
Open 25.17
Bid (Size) 24.27 (3)
Ask (Size) 24.53 (1)
Prev. Close 25.04
Today's Range 24.28 - 25.32
52wk Range 20.76 - 59.24
Shares Outstanding 62,027,061
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-30.71%
-30.71%
1 Month
-6.53%
-6.53%
3 Month
-6.31%
-6.31%
6 Month
+7.94%
+7.94%
1 Year
-18.07%
-18.07%

More News

Read More
Schrödinger to Announce First Quarter 2024 Financial Results on May 1
From Schrödinger
Via Business Wire
Critical Insights From Schrodinger Analyst Ratings: What You Need To Know
Via Benzinga
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Invest Like Bill Gates With These 3 AI Stocks to Buy
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Shhh! 7 Small-Cap Stocks That Can Double by 2025
Via InvestorPlace
Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Billionaire Bill Gates Has 35% of His Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks: Are They No-Brainer Buys?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
The Hot List: 3 AI Stocks Worth Buying on Weakness
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Okta Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Shoals Technologies Posts Weak Q4 Results, Joins Butterfly Network, Schrödinger And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
From Schrödinger
Via Business Wire
Schrödinger to Participate in Upcoming Investor Conferences
From Schrödinger
Via Business Wire
Double Your Money: 3 Growth Stocks to Grab in 2024
Via InvestorPlace
Earnings Scheduled For February 28, 2024
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
From Schrödinger
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.